Gregory Montoya, MD
Psychiatry · Texarkana, TXNPI 1083614176
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 626 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,227, 6.8 times the $476 reported in 2019. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 626 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$1K
- AbbVie$1K
- plus $2K from 13 others
What the payments were for
- Food & beverage$9,372100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 74 | $1,388 |
| Vanda Pharmaceuticals Inc. | 57 | $1,261 |
| Neurocrine Biosciences, Inc. | 58 | $1,174 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 86 | $1,146 |
| Alkermes, Inc. | 81 | $1,114 |
| AbbVie | 137 | $1,006 |
| Teva Pharmaceuticals USA, Inc. | 33 | $542 |
| Indivior Inc. | 22 | $426 |
| Sunovion Pharmaceuticals Inc. | 28 | $416 |
| Johnson & Johnson | 19 | $361 |
| E.r. Squibb & Sons, L.L.C. | 20 | $356 |
| Supernus Pharmaceuticals, Inc. | 3 | $42 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Lundbeck LLC | 2 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Noven Therapeutics, LLC | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$9,377 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 15 | $127,240 |
| Invega SustennaPaliperidone Palmitate | 20 | $63,912 |
| VraylarCariprazine Hcl | 12 | $19,335 |
| TrintellixVortioxetine Hydrobromide | 12 | $6,058 |
| Aripiprazole | 83 | $4,959 |
| Ziprasidone Hcl | 48 | $3,980 |
| Divalproex Sodium | 47 | $2,189 |
| Divalproex Sodium ErDivalproex Sodium | 26 | $1,626 |
| Olanzapine | 40 | $1,156 |
| Fluoxetine Hcl | 92 | $1,126 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 23 | $1,045 |
| Clonazepam | 92 | $1,039 |
| Buspirone Hcl | 66 | $921 |
| Oxcarbazepine | 12 | $781 |
| Benztropine Mesylate | 44 | $696 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,174 | $127,24015 claims |
| Johnson & JohnsonInvega Sustenna | $361 | $63,91220 claims |
| AbbVieVraylar | $1,006 | $19,33512 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $14 | $6,05812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Texarkana
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
- Alice MaoHouston$850K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.